Education
About Us
Working with TipRanks
Follow Us
AxoGen (AXGN)
NASDAQ:AXGN
AXGN Stock Chart & Stats
$15.87
>-$0.01(>-0.01%)
At close: 4:00 PM EST
$15.87
>-$0.01(>-0.01%)
Day’s Range― - ―
52-Week Range$9.22 - $21.00
Previous CloseN/A
Volume66.42K
Average Volume (3M)899.27K
Market Cap
$735.74M
Enterprise Value$552.86M
Total Cash (Recent Filing)$35.92M
Total Debt (Recent Filing)$68.19M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Oct 29, 2025EPS Estimate
0.07Last Dividend Ex-Date
Jan 27, 2010Dividend YieldN/A
Share Statistics
EPS (TTM)0.12
Shares Outstanding46,012,573
10 Day Avg. Volume951,403
30 Day Avg. Volume899,274
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue2.72
Enterprise Value/Gross Profit3.66
Enterprise Value/Ebitda51.01
Forecast
1Y Price Target
$24.57Price Target Upside54.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Financial PerformanceManagement expects positive net cash flow for full-year 2025.
Market PenetrationThe expected BLA approval for Avance Nerve Graft is seen as a catalyst for growth and market penetration.
Revenue GrowthThe company raised its FY25 sales growth guidance to at least 17%.
Bears Say
Guidance ConcernsAXGN did not make any comments or updates to its existing 2025 guidance, which could be seen as a lack of new positive information.
Regulatory DelaysThe government shutdown poses risks of FDA delays due to funding issues and potential backlog.
Regulatory UncertaintyThe delayed PDUFA date adds some additional uncertainty on the setup through year-end.
AxoGen News
AXGN FAQ
What was AxoGen’s price range in the past 12 months?
AxoGen lowest stock price was $9.21 and its highest was $21.00 in the past 12 months.
What is AxoGen’s market cap?
AxoGen’s market cap is $735.74M.
When is AxoGen’s upcoming earnings report date?
AxoGen’s upcoming earnings report date is Oct 29, 2025 which is in 13 days.
How were AxoGen’s earnings last quarter?
AxoGen released its earnings results on Aug 05, 2025. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.064 by $0.056.
Is AxoGen overvalued?
According to Wall Street analysts AxoGen’s price is currently Undervalued.
Does AxoGen pay dividends?
AxoGen pays a Notavailable dividend of $1 which represents an annual dividend yield of N/A. See more information on AxoGen dividends here
What is AxoGen’s EPS estimate?
AxoGen’s EPS estimate is 0.07.
How many shares outstanding does AxoGen have?
AxoGen has 46,012,573 shares outstanding.
What happened to AxoGen’s price movement after its last earnings report?
AxoGen reported an EPS of $0.12 in its last earnings report, beating expectations of $0.064. Following the earnings report the stock price went up 9.323%.
Which hedge fund is a major shareholder of AxoGen?
Currently, no hedge funds are holding shares in AXGN
AxoGen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.57 (54.82% Upside)
$24.57 (54.82% Upside)
Blogger Sentiment
Bullish
AXGN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 23.1%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.98%
12-Months-Change
Fundamentals
Return on Equity
-4.48%
Trailing 12-Months
Asset Growth
8.74%
Trailing 12-Months
Company Description
AxoGen
AxoGen, Inc. is a biotechnology company focused on the development and commercialization of innovative surgical solutions for peripheral nerve repair. Operating primarily in the healthcare sector, AxoGen provides a range of products that facilitate nerve repair and regeneration, including allograft and synthetic nerve conduits. Their core products, such as Avance® Nerve Graft and AxoGuard® Nerve Connector, are designed to enhance recovery and functional outcomes for patients undergoing surgical procedures involving nerve damage.
AXGN Company Deck
AXGN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong revenue growth and successful strategic execution, particularly in high potential accounts and surgeon training. Challenges remain with gross margin pressures and potential logistical changes due to the BLA approval process. However, the overall financial performance and raised guidance indicate a positive trajectory.View all AXGN earnings summariesAXGN Stock 12 Month Forecast
Average Price Target
$24.57
▲(54.82% Upside)
Technical Analysis
Ownership Overview
1.82% Insiders
18.44% Mutual Funds
37.38% Other Institutional Investors
29.22% Public Companies and
Individual Investors